|Title of study||
Prostate cancer Immune profiling before, during and after HDR-brachytherapy in local relapsed prostate cancer
1.5, 14 January 2020
Dr. B.G.L. Vanneste
To investigate if HDR-brachytherapy of prostate cancer will create leverage points for different forms of IO.
To investigate the increased expression of PD-(L)-1 receptor induced by HDR-brachytherapy in prostate tumor biopsies of local relapses of prostate cancer.
The presence of CXCL12, IL-23 receptor and MDSC infiltration in the tumor at 4 different time points (before and after the 1st fraction; before the 2nd and 3rd fraction of the salvage treatment). Furthermore, changes in T cell infiltration, and HLA class I-A,B,C expression on tumor cells will be examined. The tissue and the plasma will be collected and stored for further research in the future.